On September 1, Novartis AG rose 6.73% in regular trading, trading at $162.87/share, with turnover of $89.6184 million. The rally was primarily driven by the announcement that its multiple sclerosis oral drug remibrutinib met primary endpoints in two Phase 3 clinical trials.

Novartis AG disclosed that remibrutinib significantly reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis, and demonstrated superiority on all key secondary measures. A preplanned combined analysis also showed a positive trend in three-month confirmed disability progression and nominally significant results for six-month confirmed disability progression. Notably, remibrutinib demonstrated a favorable safety profile with no liver safety signal, a key concern for BTK inhibitors in development.

Separately, Novartis AG confirmed that its oncology CAR-T pipeline remains unaffected by precautionary pauses in autoimmune CAR-T trials, with the company collaborating with an independent safety committee and regulators on a comprehensive safety assessment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)